The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials

BackgroundOrally effective therapeutics for plaque psoriasis with improved response rates, lower toxicity and costs are needed in clinical practices. This study aims to assess the efficacy and safety of the recently approved TYK2 inhibitor deucravacitinib in adults with moderate to severe plaque pso...

Full description

Bibliographic Details
Main Authors:	Jingyue Qiu, Jiakuo Liu, Wenwen Liu, Fei Lin, Ning Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Medicine
Subjects:	TYK2 inhibitor deucravacitinib psoriasis autoimmune disease meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1264667/full

Similar Items

Deucravacitinib in the treatment of psoriasis
by: Tomás Estevinho, et al.
Published: (2023-12-01)

Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
by: David A. De Luca, et al.
Published: (2024-12-01)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023-05-01)

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
by: Brandon Johnson, et al.
Published: (2024-09-01)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023-05-01)

Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults
by: Reinaldo S. Dos Santos, et al.
Published: (2023-10-01)

Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
by: Lise Torp Jensen, et al.
Published: (2023-11-01)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
by: Shan Jing, et al.
Published: (2023-11-01)

Treatment of hypertrophic lichen planus using deucravacitinib
by: Siddhartha Sood, HBSc, et al.
Published: (2024-09-01)

Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
by: Joseph F. Merola, et al.
Published: (2025-02-01)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023-07-01)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024-10-01)

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024-12-01)

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
by: April W. Armstrong, et al.
Published: (2023-10-01)

Discoid lupus erythematosus successfully treated with deucravacitinib
by: Nnenna Ezeh, MD, et al.
Published: (2024-07-01)

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
by: Ian M. Catlett, et al.
Published: (2024-09-01)

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
by: April W. Armstrong, et al.
Published: (2024-06-01)

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2024-12-01)

Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation
by: Pottabattula Mahesh, et al.
Published: (2023-07-01)

A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis
by: Francisco Gómez-García, et al.
Published: (2022-02-01)

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
by: Arianna Zhang, BS, et al.
Published: (2024-03-01)

Dual‐Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self‐Locking Microneedles
by: Zi Yi Wang, et al.
Published: (2024-12-01)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
by: Ana Martins, et al.
Published: (2023-05-01)

TYK2 in Immune Responses and Treatment of Psoriasis
by: Shang L, et al.
Published: (2022-09-01)

Treatment of oral lichen planus using deucravacitinib
by: Mindy Vu, BS, et al.
Published: (2024-02-01)

A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways
by: Celia X.-J. Chen, et al.
Published: (2023-10-01)

Pityriasis rosea-like drug eruption secondary to deucravacitinib
by: Nisal Punchihewa, MD, et al.
Published: (2024-11-01)

Association of tyrosine kinase 2 polymorphisms with susceptibility to microscopic polyangiitis in a Guangxi population
by: Binglan Yang, et al.
Published: (2024-12-01)

Reactive oxygen species-responsive supramolecular deucravacitinib self-assembly polymer micelles alleviate psoriatic skin inflammation by reducing mitochondrial oxidative stress
by: Leiqing Yao, et al.
Published: (2024-05-01)

Mesenchymal stem cells alleviate psoriasis-like dermatitis in mice by inhibiting TYK2 phosphorylation
by: Lina LIANG, et al.
Published: (2022-06-01)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
by: Dionysis Nikolopoulos, et al.
Published: (2023-06-01)

JAK Inhibitors in Psoriatic Disease
by: Megna M, et al.
Published: (2023-10-01)

The efficacy and safety of deucravacitinib compared to methotrexate, in patients with vulvar lichen planus who have failed topical therapy with potent corticosteroids: a study protocol for a single-centre double-blinded randomised controlled trial
by: Marlene Wijaya, et al.
Published: (2024-03-01)

Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis
by: Yuanyuan Xu, et al.
Published: (2023-06-01)

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
by: Nicolo Costantino Brembilla, et al.
Published: (2023-05-01)

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
by: Dominika Hromadová, et al.
Published: (2021-07-01)

Neutrophil/lymphocyte ratio as serum inflammatory biomarker in patients with moderate-to-severe plaque psoriasis
by: Maria E. Agapito-Valgas, et al.
Published: (2023-04-01)

Role of tyrosine kinase 2 signals during progression of psoriasis
by: Ryuta Muromoto, et al.
Published: (2022-12-01)

JAK inhibitors ∼ overview∼
by: Hideto Kameda
Published: (2023-07-01)

Rare Association of Dermatitis Herpetiformis and Chronic Plaque Psoriasis
by: Fatima Ezzahraa Chekairi, et al.
Published: (2024-12-01)